DexCom (NASDAQ:DXCM) Stock Unloaded Sen. Tina Smith

Senator Tina Smith (Democratic-Minnesota) recently sold shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in DexCom stock on May 7th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 4/29/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

DexCom Price Performance

Shares of DexCom stock opened at $59.33 on Tuesday. The firm has a market cap of $22.89 billion, a PE ratio of 25.35, a PEG ratio of 1.04 and a beta of 1.40. The stock has a 50 day moving average of $64.54 and a 200 day moving average of $66.16. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. On average, research analysts expect that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.28% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on DXCM shares. Truist Financial reissued a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. BTIG Research reiterated a “buy” rating and issued a $85.00 price target on shares of DexCom in a research report on Monday, March 9th. Citigroup reissued a “buy” rating and set a $79.00 price objective (down from $84.00) on shares of DexCom in a research note on Monday, May 4th. Finally, Canaccord Genuity Group set a $100.00 price objective on DexCom and gave the company a “buy” rating in a research report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.50.

Hedge Funds Weigh In On DexCom

Institutional investors have recently modified their holdings of the stock. Trust Co. of Vermont lifted its holdings in shares of DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after buying an additional 145 shares during the period. CVA Family Office LLC raised its holdings in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after acquiring an additional 172 shares in the last quarter. Essex Financial Services Inc. lifted its stake in DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after acquiring an additional 175 shares during the period. Finally, IFP Advisors Inc grew its holdings in DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after acquiring an additional 178 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.